Outlining a five-year biomedical plan, China wants to expand its global role beyond just pipeline innovation.

The deal reflects a growing interest from big pharma in the compounds that bridge the gap between small molecules and biologics.

Novo will harness Anthropic’s AI assistant Claude to accelerate research and development (R&D) activities, as the drugmaker looks to regain its once-dominant position at the fro ...

WuXi XDC Cayman is to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 platform to develop an ADC candidate.

Sling is racing to market the first oral IGF-1R blocker, which would likely provide competition to Amgen’s Tepezza.

Definium Therapeutics plans to submit an NDA for LSD-based psychedelic, DT120 in generalised anxiety disorder (GAD) during H1 2027.

At ERS 2026, investigators presented their findings exploring the link between BMI and severe asthma outcomes in response to biologics.

The biosimilar candidate is intended to reference Hemlibra (emicizumab), which addresses haemophilia A, a genetic disorder. Credit: angellodeco/Shutterstock.com ...

Cheplapharm will acquire production sites in Hungary, Singapore and France. Credit: Gorodenkoff / Shutterstock.com. Cheplapharm has entered a strategic partnership to take over a portfolio of 20 ...

QurCan uses its TERP platform to facilitate non-viral delivery of genetic medicines. Credit: MrWinn / Shutterstock.com. Eli Lilly and Company and QurCan Therapeutics have signed an exclusive research ...

Imdelltra is a targeted immunotherapy designed to bind to DLL3 proteins, activating the immune system to target SCLC cells. Credit: MY STOCKERS/Shutterstock.com. The US Food and Drug Administration ...